Safety and efficacy of inhalable ambroxol hydrochloride aerosol for adult patients with respiratory diseases: an open-label, single-arm, multicentre study.
Jinfang Ma, Jinping Zheng, Liping Chen, Zhengguang He, Zuke Xiao, Xiaohong Yang, Gang Chen, Changli Yu, Tianli Wang, Dan Zhu, Liangping Mao, Wei Wang, Zhenshan Wang, Xiaoju Zhang, Jie Meng, Xianwei Ye, Rui Chen, Jianqing Zhao, Ting Yang, Keying Xue, Zhiyi He, Baosong Xie, Xiaohong Chen, Ruifeng Zhang, Yuanlin Song, Weiquan Liang, Lin Su, Huili Zhu, Wanjun Yu, Yilan Sun, Jie Zhang, Xiaoping Ren, Faguang Jin, Shujuan Jiang, Tiantuo Zhang, Yi Hu, Zhancheng Gao, Gongping Chen
{"title":"Safety and efficacy of inhalable ambroxol hydrochloride aerosol for adult patients with respiratory diseases: an open-label, single-arm, multicentre study.","authors":"Jinfang Ma, Jinping Zheng, Liping Chen, Zhengguang He, Zuke Xiao, Xiaohong Yang, Gang Chen, Changli Yu, Tianli Wang, Dan Zhu, Liangping Mao, Wei Wang, Zhenshan Wang, Xiaoju Zhang, Jie Meng, Xianwei Ye, Rui Chen, Jianqing Zhao, Ting Yang, Keying Xue, Zhiyi He, Baosong Xie, Xiaohong Chen, Ruifeng Zhang, Yuanlin Song, Weiquan Liang, Lin Su, Huili Zhu, Wanjun Yu, Yilan Sun, Jie Zhang, Xiaoping Ren, Faguang Jin, Shujuan Jiang, Tiantuo Zhang, Yi Hu, Zhancheng Gao, Gongping Chen","doi":"10.1136/bmjresp-2023-002096","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Airway mucus hypersecretion is a key pathophysiological feature in many respiratory diseases and could lead to airway obstruction and repeated infections, consequently accelerating disease progression, which impacts on pulmonary function and quality of life (QoL), highlighting the importance of mucolytic therapy targeting airway mucus hypersecretion.</p><p><strong>Objectives: </strong>To investigate the safety and efficacy of inhalable ambroxol hydrochloride aerosol for adult patients with respiratory diseases.</p><p><strong>Design: </strong>An open-label, single-arm, multicentre postmarketing surveillance study.</p><p><strong>Methods: </strong>Adult patients with acute or chronic respiratory diseases were eligible to receive aerosol inhalation of ambroxol hydrochloride (3 mL and 7.5 mg/mL) using a nebuliser two times per day given at least 6 hours apart between doses. The treatment lasted for a maximum of 7 days. The primary safety outcome was the frequency and severity of adverse events (AEs), and the primary efficacy outcome was changes in sputum scale scores.</p><p><strong>Results: </strong>Among 1201 eligible patients, 1192 received study medication and were included in the full analysis set and the safety set. Any grade AEs occurred in 16.3% of the patients, including serious AEs in four (0.3%) patients. The three most frequent AEs were respiratory symptoms and signs (1.5%), nausea and vomiting (0.8%) and digestive tract symptoms and signs (0.7%). In the full analysis set, the patients showed a mean reduction of 77.6% (95% CI, 75.9% to 79.3%) in the sputum scale score at the end of treatment, with a mean difference of -1.7±0.7 from baseline (p<0.001).</p><p><strong>Conclusion: </strong>Inhalable ambroxol hydrochloride aerosol is well tolerated and effective in easing expectoration and alleviating cough, reducing sputum and improving the QoL of adult patients with acute and chronic respiratory diseases.</p><p><strong>Trial registration number: </strong>ChiCTR2100043736.</p>","PeriodicalId":9048,"journal":{"name":"BMJ Open Respiratory Research","volume":"12 1","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12083361/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Open Respiratory Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/bmjresp-2023-002096","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Airway mucus hypersecretion is a key pathophysiological feature in many respiratory diseases and could lead to airway obstruction and repeated infections, consequently accelerating disease progression, which impacts on pulmonary function and quality of life (QoL), highlighting the importance of mucolytic therapy targeting airway mucus hypersecretion.
Objectives: To investigate the safety and efficacy of inhalable ambroxol hydrochloride aerosol for adult patients with respiratory diseases.
Design: An open-label, single-arm, multicentre postmarketing surveillance study.
Methods: Adult patients with acute or chronic respiratory diseases were eligible to receive aerosol inhalation of ambroxol hydrochloride (3 mL and 7.5 mg/mL) using a nebuliser two times per day given at least 6 hours apart between doses. The treatment lasted for a maximum of 7 days. The primary safety outcome was the frequency and severity of adverse events (AEs), and the primary efficacy outcome was changes in sputum scale scores.
Results: Among 1201 eligible patients, 1192 received study medication and were included in the full analysis set and the safety set. Any grade AEs occurred in 16.3% of the patients, including serious AEs in four (0.3%) patients. The three most frequent AEs were respiratory symptoms and signs (1.5%), nausea and vomiting (0.8%) and digestive tract symptoms and signs (0.7%). In the full analysis set, the patients showed a mean reduction of 77.6% (95% CI, 75.9% to 79.3%) in the sputum scale score at the end of treatment, with a mean difference of -1.7±0.7 from baseline (p<0.001).
Conclusion: Inhalable ambroxol hydrochloride aerosol is well tolerated and effective in easing expectoration and alleviating cough, reducing sputum and improving the QoL of adult patients with acute and chronic respiratory diseases.
期刊介绍：
BMJ Open Respiratory Research is a peer-reviewed, open access journal publishing respiratory and critical care medicine. It is the sister journal to Thorax and co-owned by the British Thoracic Society and BMJ. The journal focuses on robustness of methodology and scientific rigour with less emphasis on novelty or perceived impact. BMJ Open Respiratory Research operates a rapid review process, with continuous publication online, ensuring timely, up-to-date research is available worldwide. The journal publishes review articles and all research study types: Basic science including laboratory based experiments and animal models, Pilot studies or proof of concept, Observational studies, Study protocols, Registries, Clinical trials from phase I to multicentre randomised clinical trials, Systematic reviews and meta-analyses.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
